Mobilisation of hematopoietic CD34+ precursor cells in patients with acute stroke is safe--results of an open-labeled non randomized phase I/II trial.

URN to cite this document:: urn:nbn:de:bvb:355-epub-237509
DOI to cite this document:: 10.5283/epub.23750

Boy, Sandra ; Sauerbruch, Sophie ; Kraemer, Mathias ; Schormann, Thorsten ; Schlachetzki, Felix ; Schuierer, Gerhard ; Luerding, Ralph ; Hennemann, Burkhard ; Orso, Evelyn ; Dabringhaus, Andreas ; Winkler, Jürgen ; Bogdahn, Ulrich

Preview

PDF
(319kB)

Date of publication of this fulltext: 11 Apr 2012 09:06

Alternative links to fulltext:Pubmed DOI

Details

Preview

Indexed in

Export bibliographical data

Abstract

Background: Regenerative strategies in the treatment of acute stroke may have great potential. Hematopoietic growth factors mobilize hematopoietic stem cells and may convey neuroprotective effects. We examined the safety, potential functional and structural changes, and CD34(+) cell-mobilization characteristics of G-CSF treatment in patients with acute ischemic stroke. Methods and Results: Three ...